Rosen Law Firm is actively recruiting investors who purchased shares of uniQure N.V. (NASDAQ: QURE) during a specified period to participate in an ongoing securities class action lawsuit. The litigation centers on allegations that the gene therapy company made material misrepresentations regarding FDA approval of its Pivotal Study design and understated timeline delays affecting its Biologics License Application submission.
According to the complaint, uniQure investors claim the company provided incomplete or misleading disclosures about the regulatory status and expected approval pathway for its therapeutic programs. The case name and specific dates of the alleged misstatements have been established through the class certification process, with institutional and individual shareholders eligible to join the action.
Investors who purchased uniQure shares during the relevant period are advised to contact qualified securities counsel before the April 13, 2026 lead plaintiff deadline. The firm notes that participation in class action litigation does not require out-of-pocket costs for individual shareholders, as attorney fees are typically recovered from any settlement or judgment award.